Charles Schwab Investment Management Inc Provention Bio, Inc. Transaction History

Charles Schwab Investment Management Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$6.7 - $24.21 $16,669 - $60,234	2,488 Added 1.41%	178,952 $4.31 Million
Q4 2022 Feb 13, 2023	BUY	$4.52 - $10.57 $51,338 - $120,054	11,358 Added 6.88%	176,464 $1.87 Million
Q3 2022 Nov 14, 2022	BUY	$3.43 - $5.62 $72,366 - $118,570	21,098 Added 14.65%	165,106 $743,000
Q2 2022 Aug 15, 2022	SELL	$3.65 - $7.3 $7,500 - $15,001	-2,055 Reduced 1.41%	144,008 $577,000
Q1 2022 May 13, 2022	BUY	$3.4 - $7.88 $8,625 - $19,991	2,537 Added 1.77%	146,063 $1.07 Million
Q4 2021 Feb 11, 2022	BUY	$5.59 - $7.39 $28,889 - $38,191	5,168 Added 3.74%	143,526 $807,000
Q3 2021 Nov 16, 2021	SELL	$5.66 - $8.33 $1.34 Million - $1.97 Million	-236,596 Reduced 63.1%	138,358 $886,000
Q2 2021 Aug 16, 2021	BUY	$6.71 - $11.04 $73,306 - $120,611	10,925 Added 3.0%	374,954 $3.16 Million
Q1 2021 May 17, 2021	BUY	$10.12 - $19.45 $477,997 - $918,681	47,233 Added 14.91%	364,029 $3.82 Million
Q4 2020 Feb 16, 2021	BUY	$11.79 - $18.94 $26,598 - $42,728	2,256 Added 0.72%	316,796 $5.37 Million
Q3 2020 Nov 13, 2020	BUY	$10.34 - $15.2 $2.2 Million - $3.23 Million	212,320 Added 207.71%	314,540 $4.04 Million
Q2 2020 Aug 14, 2020	BUY	$7.81 - $17.0 $684,679 - $1.49 Million	87,667 Added 602.4%	102,220 $1.44 Million
Q4 2019 Feb 07, 2020	BUY	$5.84 - $14.9 $84,989 - $216,839	14,553 New	14,553 $217,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.